Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berns, J. S.
Right arrow Articles by Rudnick, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berns, J. S.
Right arrow Articles by Rudnick, M. R.

Journal of the American Society of Nephrology, Vol 1, Issue 9 1061-1080, Copyright © 1991 by American Society of Nephrology

REVIEWS

Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections

JS Berns, RM Cohen, RJ Stumacher and MR Rudnick
Division of Nephrology and Hypertension, Graduate Hospital, Philadelphia, PA 19146.

Patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome are often treated with a variety of potentially nephrotoxic drugs. This review summarizes the renal, fluid, and electrolyte complications of drugs used to treat human immunodeficiency virus and associated opportunistic infections. The pharmacokinetics of the drugs are also briefly reviewed, and dosing guidelines for the use of these drugs in patients who have renal insufficiency or who are receiving dialysis are provided.


This article has been cited by other articles:


Home page
 CJASNHome page
J. S. Berns and N. Kasbekar
Highly Active Antiretroviral Therapy and the Kidney: An Update on Antiretroviral Medications for Nephrologists
Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 117 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Le Meur, S. Mons, C. Moesch, and C. Leroux-Robert
The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation
Nephrol. Dial. Transplant., March 1, 2000; 15(3): 442 - 442.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673